{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:15Z","timestamp":1792788435780,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:00:00Z","timestamp":1566259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"the Academy of Finland","doi-asserted-by":"publisher","award":["1309455"],"award-info":[{"award-number":["1309455"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"the Academy of Finland","doi-asserted-by":"publisher","award":["288671"],"award-info":[{"award-number":["288671"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Business Finland","id":[{"id":"https:\/\/ror.org\/05bgf9v38","id-type":"ROR","asserted-by":"crossref"}]},{"name":"THERDIAB","award":["1843\/31\/2014"],"award-info":[{"award-number":["1843\/31\/2014"]}]},{"name":"Swedish Child Diabetes Foundation"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vaccine.2019.08.037","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T07:55:01Z","timestamp":1566892501000},"page":"5962-5971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine"],"prefix":"10.1016","volume":"37","author":[{"given":"Minna M.","family":"Hankaniemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir-Babak","family":"Sioofy-Khojine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9374-4583","authenticated-orcid":false,"given":"Suvi","family":"Heinim\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varpu","family":"Marjom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Hy\u00f6ty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Blazevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli H.","family":"Laitinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Flodstr\u00f6m-Tullberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9357-1480","authenticated-orcid":false,"given":"Vesa P.","family":"Hyt\u00f6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2019.08.037_b0005","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/fmb.11.40","article-title":"Viral myocarditis: potential defense mechanisms within the cardiomyocyte against virus infection","volume":"6","author":"Yajima","year":"2011","journal-title":"Future Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.08.037_b0010","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/jmv.21998","article-title":"Coxsackievirus B3-associated aseptic meningitis: an emerging infection in Hong Kong","volume":"83","author":"Wong","year":"2011","journal-title":"J Med Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.08.037_b0015","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1089\/vim.2004.17.358","article-title":"Coxsackievirus-induced pancreatitis","volume":"17","author":"Huber","year":"2004","journal-title":"Viral Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2019.08.037_b0020","first-page":"1","article-title":"Centers for disease control and prevention. enterovirus surveillance\u2013United States, 1970\u20132005","volume":"55","author":"Khetsuriani","year":"2006","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2019.08.037_b0025","first-page":"223","article-title":"Pediatric group B coxsackievirus infections","volume":"323","author":"Romero","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.08.037_b0030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/db13-0619","article-title":"Coxsackievirus B1 is associated with induction of beta-cell autoimmunity that portends type 1 diabetes","volume":"63","author":"Laitinen","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2019.08.037_b0035","doi-asserted-by":"crossref","DOI":"10.1080\/14760584.2018.1548281","article-title":"Developing a vaccine for Type 1 diabetes by targeting coxsackievirus B","author":"Hyoty","year":"2018","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2019.08.037_b0040","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-018-4561-y","article-title":"Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes","author":"Sioofy-Khojine","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.vaccine.2019.08.037_b0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.coph.2018.07.006","article-title":"Enteroviral infections in the pathogenesis of type 1 diabetes: new insights for therapeutic intervention","volume":"43","author":"Richardson","year":"2018","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"10.1016\/j.vaccine.2019.08.037_b0050","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1080\/14760584.2018.1548281","article-title":"Developing a vaccine for type 1 diabetes by targeting coxsackievirus B","volume":"17","author":"Hyoty","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.08.037_b0055","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-019-4811-7","article-title":"Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes","author":"Dunne","year":"2019","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.vaccine.2019.08.037_b0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40121-013-0014-6","article-title":"The problems with polio: toward eradication","volume":"2","author":"Lien","year":"2013","journal-title":"Infect Dis Ther"},{"issue":"9","key":"10.1016\/j.vaccine.2019.08.037_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph13090890","article-title":"The current status of the disease caused by enterovirus 71 Infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development","volume":"13","author":"Chang","year":"2016","journal-title":"Int J Environ Res Public Health"},{"issue":"30","key":"10.1016\/j.vaccine.2019.08.037_b0070","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1016\/j.vaccine.2017.05.057","article-title":"Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model","volume":"35","author":"Hankaniemi","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.08.037_b0075","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00125-017-4492-z","article-title":"A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes","volume":"61","author":"Stone","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.vaccine.2019.08.037_b0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2014.01.013","article-title":"Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice","volume":"104","author":"Koho","year":"2014","journal-title":"Antiviral Res"},{"issue":"9","key":"10.1016\/j.vaccine.2019.08.037_b0085","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/nprot.2007.321","article-title":"The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability","volume":"2","author":"Niesen","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1016\/j.vaccine.2019.08.037_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2018.06.012","article-title":"Intradermal and intranasal immunizations with oligomeric middle layer rotavirus VP6 induce Th1, Th2 and Th17T cell subsets and CD4(+) T lymphocytes with cytotoxic potential","volume":"157","author":"Heinimaki","year":"2018","journal-title":"Antiviral Res"},{"issue":"3","key":"10.1016\/j.vaccine.2019.08.037_b0095","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jmv.20202","article-title":"Isolation and characterisation of poliovirus mutants resistant to heating at 50 degrees Celsius for 30 min","volume":"74","author":"Shiomi","year":"2004","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.08.037_b0100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1099\/0022-1317-74-4-685","article-title":"Antigenic structure of poliovirus in inactivated vaccines","volume":"74","author":"Ferguson","year":"1993","journal-title":"J Gen Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.08.037_b0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1128\/JVI.01586-16","article-title":"Increasing Type 1 poliovirus capsid stability by thermal selection","volume":"91","author":"Adeyemi","year":"2017","journal-title":"J Virol"},{"issue":"Pt 7","key":"10.1016\/j.vaccine.2019.08.037_b0110","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1099\/vir.0.19088-0","article-title":"Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains","volume":"84","author":"Martin","year":"2003","journal-title":"J Gen Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2019.08.037_b0115","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1586\/erv.12.38","article-title":"Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges","volume":"11","author":"Delrue","year":"2012","journal-title":"Expert Rev Vacc"},{"issue":"14","key":"10.1016\/j.vaccine.2019.08.037_b0120","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/rcm.6610","article-title":"Ultraviolet laser-induced cross-linking in peptides","volume":"27","author":"Leo","year":"2013","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.vaccine.2019.08.037_b0125","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1021\/ar00113a002","article-title":"Chemical aspects of UV-induced cross-linking of proteins to nucleic acids. photoreactions with lysine and tryptophan","volume":"18","author":"Saito","year":"1985","journal-title":"Acc Chem Res"},{"issue":"4","key":"10.1016\/j.vaccine.2019.08.037_b0130","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.vaccine.2011.11.087","article-title":"Selection and characterization of vaccine strain for enterovirus 71 vaccine development","volume":"30","author":"Chang","year":"2012","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2019.08.037_b0135","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1016\/j.vaccine.2018.05.005","article-title":"The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease","volume":"36","author":"Lim","year":"2018","journal-title":"Vaccine"},{"issue":"41","key":"10.1016\/j.vaccine.2019.08.037_b0140","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.1016\/j.vaccine.2007.07.060","article-title":"Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains","volume":"25","author":"Tano","year":"2007","journal-title":"Vaccine"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2019.08.037_b0145","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1099\/vir.0.018168-0","article-title":"Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations","volume":"91","author":"Furuya","year":"2010","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.08.037_b0150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.biologicals.2018.03.002","article-title":"Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures","volume":"53","author":"White","year":"2018","journal-title":"Biologicals"},{"issue":"3","key":"10.1016\/j.vaccine.2019.08.037_b0155","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jbiosc.2013.08.015","article-title":"Evaluation of the stability of enterovirus 71 virus-like particle","volume":"117","author":"Lin","year":"2014","journal-title":"J Biosci Bioeng"},{"issue":"11","key":"10.1016\/j.vaccine.2019.08.037_b0160","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/0264-410X(95)00036-Z","article-title":"Heat stabilized, infectious poliovirus","volume":"13","author":"Ofori-Anyinam","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.037_b0165","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.virol.2015.06.006","article-title":"Recent progress in understanding coxsackievirus replication, dissemination, and pathogenesis","volume":"484","author":"Sin","year":"2015","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2019.08.037_b0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1099\/0022-1317-64-1-159","article-title":"Specificity of IgM antibodies in acute human coxsackievirus B infections, analysed by indirect solid phase enzyme immunoassay and immunoblot technique","volume":"64","author":"Dorries","year":"1983","journal-title":"J Gen Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.08.037_b0175","first-page":"455","article-title":"Coxsackievirus B-3 myocarditis. acute and chronic forms of the disease caused by different immunopathogenic mechanisms","volume":"128","author":"Lodge","year":"1987","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.vaccine.2019.08.037_b0180","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/21505594.2016.1175701","article-title":"Enterovirus infections: pivoting role of the adaptive immune response","volume":"7","author":"Bopegamage","year":"2016","journal-title":"Virulence"},{"issue":"3","key":"10.1016\/j.vaccine.2019.08.037_b0185","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1096\/fj.11-193557","article-title":"Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections","volume":"26","author":"Niespodziana","year":"2012","journal-title":"FASEB J"},{"issue":"12","key":"10.1016\/j.vaccine.2019.08.037_b0190","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.4161\/hv.21739","article-title":"Production of EV71 vaccine candidates","volume":"8","author":"Chong","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2019.08.037_b0195","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/JCM.25.8.1376-1379.1987","article-title":"Subclass restriction of human enterovirus antibodies","volume":"25","author":"Torfason","year":"1987","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2019.08.037_b0200","doi-asserted-by":"crossref","first-page":"e64024","DOI":"10.1371\/journal.pone.0064024","article-title":"Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection","volume":"8","author":"Cao","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.08.037_b0205","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2019.08.037_b0210","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.4161\/hv.29823","article-title":"Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice","volume":"10","author":"Sun","year":"2014","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T08:01:26Z","timestamp":1610870486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19311016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":42,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0264410X19311016"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}